Diagnostic and Prognostic Assessment of Suspected Drug-induced Liver Injury in Clinical Practice

Raúl J. Andrade; Mercedes Robles-Díaz


Liver International. 2020;40(1):6-17. 

In This Article

The Future

New specific biomarkers are urgently needed not only to confidently diagnose DILI but also to accurately predict it during the early phases of drug development. This would enable the development of safer drugs and a better characterization of liver safety profiles of marketed medications. In addition, this would reduce the uncertainty for physicians and patients when prescribing additional drugs within the same drug class as the causative agent. In the meantime, maintenance of existing prospective DILI cohort studies and establishing new collaborative initiatives will allow a better understanding of DILI signatures that can assist clinicians when assessing a potential case of hepatotoxicity.